Effect of a single dose of pregabalin on herpes zoster pain by Jensen-Dahm, Christina et al.
RESEARCH Open Access
Effect of a single dose of pregabalin on herpes
zoster pain
Christina Jensen-Dahm
1, Michael C Rowbotham
2, Haatem Reda
3, Karin Lottrup Petersen
4*
Abstract
Background: The effect of pregabalin on acute herpes zoster pain has not been previously evaluated.
Methods: In a randomized, double-blind, placebo-controlled, two-session crossover study the effect of a single oral
dose of pregabalin (150 mg) on pain and allodynia was evaluated in 8 subjects with herpes zoster.
Results: Over 6 hours of observation, pain decreased by a mean of 33% with pregabalin and 14% with placebo (p
< 0.10). Effects on allodynia and SF-MPQ were not significant.
Conclusions: Compared to an earlier study of gabapentin 900 mg for acute zoster pain and allodynia that
followed a nearly identical protocol, pregabalin had a similar effect on pain and was well tolerated, with no
difference from placebo on sleepiness. Common side effects of light-headedness, unsteady gait, and slowed
thinking were almost identical to that observed in the earlier study of gabapentin. Subject recruitment proved
difficult in part due to the widespread off-label use of gabapentin and pregabalin for acute zoster pain in our
region of the USA.
Trial Registration: ClinicalTrials.gov Identifier: NCT00352651
Introduction
Herpes zoster (HZ), the reactivation of latent varicella
zoster virus in sensory ganglia, produces a painful, uni-
lateral, dermatomal rash. We have previously demon-
strated that a single oral dose of gabapentin (900 mg)
reduces pain and allodynia during HZ [1]. Both pregaba-
lin and gabapentin bind to the a2δ-subunit of the
calcium channel [2], but no head-to-head efficacy com-
parisons have been made. In this randomized, placebo-
controlled, two-session, crossover study we evaluated
the effect of a single dose of 150 mg of pregablin on
pain and allodynia in subjects with HZ using a nearly
identical protocol.
Materials and methods
Subjects
All subjects provided informed written consent. The
study was approved by the UCSF Committee on Human
Research. Subjects were medically stable adults with
onset of unilateral HZ during the previous 6 weeks and
continuing pain ≥ 40 on a 100 mm pain visual analogue
scale (VAS; 0 = no pain, 100 = worst imaginable pain)
at the screening visit. Exclusion criteria included: prior
pregabalin use, nerve block therapy within the last
48 hours, use of gabapentin within the last 72 hours,
unrelated severe pain and clinically significant medical
or psychiatric disease. Stable doses of oral NSAIDs, acet-
aminophen, opioids, anticonvulsants (except pregabalin
or gabapentin) or antidepressant were allowed and
could be taken up to 2 hours prior to medication visits.
Subjects were not allowed to use topical analgesics
12 hours prior to medication visits.
Visits and measures
Following the screening visit, the two medication visits
(V1 and V2) were separated by at least 48 hours. Medica-
t i o nw a sa d m i n i s t e r e dd o u b l e - b l i n da sas i n g l ed o s eo f
150 mg of pregabalin or identical-appearing placebo.
Randomization was computer generated and managed by
a study pharmacist not otherwise involved in the study.
Subjects rated their pain on the 100 mm pain VAS. Allo-
dynia area was mapped by stimulating the skin with a
1-inch foam brush going from normal to affected skin.
Within the area of greatest pain, the intensity of allodynia
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100 = most unpleasant imaginable) was rated after 3
strokes with the foam brush. Subjects rated side-effects
(sleepiness, light-headedness or dizziness, unsteady gait,
nausea and vomiting) on a 0-3 scale (0 = none, 1 = mild,
2 = moderate, 3 = severe). Pain, allodynia intensity and
side-effects were rated prior to medication and every 30
minutes for 6 hours. Allodynia areas were mapped at
1,2,3, and 6 hours post-medication. The Short Form
McGill Pain Questionnaire was administered pre-medica-
tion and 2 hours post-medication [3].
Statistical analysis
In a previous study a single 900 mg dose of oral gabapen-
tin reduced HZ pain by approximately 33% (compared to
placebo). The standard deviation of the change was 50%,
resulting in a standardized effect size (E/S) of 0.7. With a
two-tailed a of 0.05, and a b o f0 . 2 ,t h es a m p l es i z e
desired is 34. The primary efficacy variable, VAS pain,
was analyzed using a model that included fixed effects for
treatment, age, treatment order, sex, and baseline pain
and a random subject effect to account for correlated
data between the two treatments. A similar analysis was
used for other, secondary, repeated measures. Post hoc
analyses of percent reduction from baseline at each time
point for the primary efficacy variable used the Wilcoxon
signed-rank test. SF-MPQ (total score) results were ana-
lyzed with Wilcoxon signed-rank test.
Results
Between January 2006-March 2008, 334 potential sub-
jects were telephone screened, with 26 attending a
screening visit (Figure 1). Eight subjects were dosed and
all completed the study. The study was closed in March
2008 due to the slow pace of enrollment. Baseline char-
acteristics are shown in Table 1 and changes in pain rat-
ings during the two drug administration sessions are
s h o w ni nF i g u r e2 .O v e r a l l ,t h e r ew a sat r e n dt o w a r d
greater reduction in pain after pregabalin administration
than after placebo (placebo - pregabalin: -19.0% [95%
CI: -42.5% to +4.5%]; p = 0.096. Analysis of the indivi-
dual time points for the difference between pregabalin
and placebo revealed significance at 1.5 hours after
medication administration (-23.5% [- 44.5% to -2.5%]; p
= 0.034), and trends at 2.5 hours (-31.9% [-70.1% to
+6.3%]; p = 0.099) and 5 hours (-43.7% [-91.2% to
+3.9%]; p = 0.076). Relative to placebo, we found a
trend towards greater maximal pain reduction with
pregabalin (-22.9% [-52.0 to + 6.0); p = 0.100). Changes
in severity and area of allodynia, and the change in SF-
MPQ scores, were not significantly different between
the pregabalin and placebo sessions (data in Table 2).
Side-effects were well tolerated (Table 2).
Discussion
Pregabalin has not been previously studied for acute zos-
ter pain. Pregabalin has been studied in Post Herpetic
Neuralgia (PHN), the chronic neuropathic pain condition
afflicting some patients after an episode of herpes zoster
(HZ). In multiple clinical trials for PHN, pregabalin has
been proven effective at daily doses of 150 mg/day and
higher [4,5]. Efficacy is demonstrable within a few days of
starting treatment [4]. In one large trial, changes in allo-
dynia severity correlated with changes in ongoing pain
Phone Screen (334) 
HZ –  
screened (26) 
HZ –  
not interested (35) 
Excluded based on 
 phone interview (273) 
Included (8)  Excluded (18) * 
Completed (8) 
PHN (105)  HZ > 6 weeks (40) 
HZ not enough 
 pain (38)   Other reasons (67) 
HZ on pregabalin or 
gabapentin (23) 
Figure 1 CONSORT Statement. * Screened subjects excluded before randomization due to: not enough pain (1), BMI < 20 (1), creatinine
clearance <60 ml/min (2), significant medical or psychiatric illness (4), medication (1), unclear diagnosis (1), withdrew consent (8).
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sent study, there was a trend towards a greater reduction
in pain after a single dose of 150 mg of pregabalin. Using
the data given in table 2, the standardized effect size is
1 . 1 6 .W i t ht h i se f f e c ts i z ea n dat w o - s i d e da of 0.05 and
b o f0 . 2 ,af u t u r es t u d yw o u l dn e e do n l y1 8s u b j e c t st o
reach significance. A significant effect of pregabalin on
allodynia severity or area was not demonstrated.
A previous study of nearly identical design conducted
in our unit included 26 subjects with HZ and showed
Table 1 Baseline demographics, pain and allodynia
Placebo first group, n = 3 Pregabalin first group, n = 5
Demographics
Age; median (range) 77 (73-84) 65 (22-76)
% Female 33% 40%
Distribution of Zoster
Trigeminal 0 1
Cervical 1 1
Thoracic 2 3
Severity of rash
Mild 0 0
Moderate 100%
a 80%
Severe 20%
Days between outbreak and study entry; median (range) 31 (31-37) 23 (10-45
b)
Days between visit 1 and visit 2; median (range) 2 (2-5) 2 (2-5)
Pain at V1, 0-100; median (range) 63 (20-90) 48 (16-90)
Pain at V2, 0-100; median (range) 55 (17-79) 30 (9-94)
Allodynia severity V1, 0-100; median (range) 51 (19-74) 37 (10-84)
Allodynia severity V2, 0-100; median (range) 20 (15-48) 34 (0-70)
aOne subject missing,
b One subject included at 45 days; met all other inclusion criteria.
*
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Figure 2 Percent reduction in median pain VAS (placebo and pregabalin) at specific time points after medication administration.A
larger negative number means greater reduction in pain. * p < 0.05.
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pain and allodynia [1]. In the present study, the maxi-
mum percent reduction in pain with pregabalin was 63%
compared to 40% with placebo, quite similar to the 66%
reduction with gabapentin and 33% reduction with pla-
cebo in the earlier study. The pattern of side effects was
quite similar between the two studies, with the note-
worthy exception that sleepiness was greater than pla-
cebo with gabapentin, and identical to placebo with
pregabalin. Trials using a single relatively large dose have
only limited ability to predict longer term treatment
results. The recent multicenter trial by Dworkin and col-
leagues in 87 subjects treated within 6 days of zoster rash
onset compared placebo, oxycodone, and gabapentin up
to 600 mg three times a day [6]. Gabapentin therapy
showed a trend for efficacy in the first week which was
completely lost as the trial continued, while pain reduc-
tion with oxycodone remained significantly greater than
with placebo. However, the natural history of the decline
in pain complicates longer-term trials in HZ patients. At
treatment day 9 in the Dworkin et al study, even ‘worst
pain’ in the placebo group was already below 4/10.
When evaluating efficacy of new compounds for neu-
ropathic pain in HZ and PHN, baseline pain ratings
should be at least moderate to severe to allow measure-
ment of pain relief. Herpes zoster is much more com-
mon than PHN, with well over a million new cases each
year in the USA, and in the study of Helgason and col-
leagues, between 7%-30% of subjects reported their
acute zoster pain as moderate to severe [7]. The inci-
dence of moderate to severe PHN after HZ is lower; in
the landmark vaccine study by Oxman and colleagues,
the incidence of PHN (worst pain >/= 3/10) was 5.1% at
6 months in placebo vaccinated subjects aged 60 or
older [8]. However, as PHN pain is chronic and often
insufficiently treated, the point prevalence of patients
looking to participate in clinical trials may indeed be
larger than the point prevalence of patients with moder-
ate-severe HZ pain, many of whom are hoping the pain
will spontaneously subside. When considering whether
to study HZ or PHN, it should also be kept in mind
that the neurodestructive and inflammatory aspects of
herpes zoster might make this condition respond differ-
ently to treatment than chronic neuropathic pain disor-
ders such as PHN and painful diabetic neuropathy.
Recruitment is always an important issue in clinical
trials, and this study demonstrates that recruitment
challenges can be severe. During an enrolment period of
more than 2 years, we phone screened 334 subjects yet
dosed a total of 8. Only 162 were within the specified
time frame after rash onset for study inclusion and
others had insufficient pain. Unlike trials of investigational
compounds not otherwise available, many otherwise eligi-
ble subjects declined to participate because pregabalin
could be obtained from their primary physician, or they
had current or prior treatment with pregabalin or gaba-
pentin for their HZ pain (frequently initiated at the time
of zoster diagnosis). We used only print newspaper and
online advertising (Craigslist). Recruiting within emer-
gency rooms, primary care clinics, and dermatology prac-
tices might yield untreated and potentially eligible subjects
within the first few days of rash onset.
Conclusions
In summary, this small placebo-controlled crossover
trial of a single relatively large dose of pregabalin
Table 2 Outcome Measures
Outcome (Mean and 95% CI) Pregabalin, n = 8 Placebo, n = 8
Overall Pain percent reduction 33.0 (13.2 - 52.9) 14.0 (-5.8 to 33.8)
Overall Pain VAS reduction 14.7 (5.1 - 24.3) 8.5 (-1.1 to 18.1)
Allodynia severity, overall percent reduction 25.2 (0.9 - 49.5) 30.7 (7.5 - 53.9)
Allodynia area, overall percentage reduction -1.4 (-59.6 to 56.8) -12.4 (-70.8 to 45.9)
Total SF McGill (0-45), premedication 12.4 (8-25) 12.3 (7-26)
Total SF McGill (0-45), post medication 7.25 (3-22) 8.9 (6-16)
Side-effects; 0 to 3
Sleepiness 0.7 (0-1.2) 0.7 (0-1.7)
Light-headedness 0.5 (0-1.6) 0.2 (0-1.1)
Unsteady gait 0.2 (0 -1.2) 0.05 (0-0.4)
Slowed thinking 0.2 (0-1) 0
Headache 0.01 (0-0.08) 0.1 (0-0.5)
Nausea 0.1 (0-1) 0.09 (0-0.4)
Vomiting 0 0
Blurry vision 0.01 (0 -0.08) 0
Total Side-effect score 1.7 (0.2 - 3.9) 1.1 (0-4.1)
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effect size was similar to that observed in a prior study
of gabapentin in a much larger group of acute zoster
patients. Greatly complicating recruitment for this pla-
cebo-controlled study was the widespread clinical prac-
tice of ‘off-label’ initiation of pregabalin or gabapentin
therapy at the time of zoster diagnosis.
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